Group 1 - The overall profitability of Ausnutria (01717) is expected to face temporary pressure due to market channel adjustments and the expansion of low-margin new businesses, leading to a downward revision of revenue and profit forecasts for 2025-2027 [1] - Revenue forecasts for 2025-2027 have been adjusted from 7.83/8.24/8.62 billion to 7.49/7.90/8.26 billion, while net profit forecasts have been revised from 300/360/430 million to 240/270/320 million [1] - The earnings per share (EPS) estimates for 2025-2027 have been lowered from 0.17/0.20/0.24 to 0.13/0.15/0.18, with a current P/E ratio of 14/12/10 times based on the closing price of HKD 1.96 on February 9, 2026 [1] Group 2 - The domestic milk powder market continues to face challenges, with a decline in the birth rate impacting growth; however, the overseas milk powder market is showing significant growth, particularly in the Middle East, North America, and the CIS regions [2] - In the first half of 2025, Ausnutria's milk powder business experienced a temporary reduction in shipment volumes due to system upgrades and inventory adjustments, leading to a forecasted decline in domestic sheep and cow milk powder business for the year [2] - The company remains optimistic about future growth, planning to expand its presence in the Middle East and continue developing offline channels like Walmart in the U.S. to create a diversified growth engine [2] Group 3 - The infant formula segment has seen success, with Haipinokai being recognized as the top-selling nutritional milk powder for three consecutive years, while Ausnutria's sheep milk powder brand, Jia Bei Ai Te, has gained recognition for its innovative marketing strategies [3] - The approval of a new strain of probiotics for infants by the National Health Commission marks a significant milestone for Jinqi Biotechnology, enhancing its reputation and technological capabilities in the infant nutrition sector [3] - The company aims to solidify its market position and expand its growth trajectory by focusing on consumer needs and leveraging research and innovation to achieve its vision of becoming the most trusted formula milk and nutrition health company globally [3]
华西证券:维持澳优(01717)“增持”评级 海外扛增长大旗